Argenx reports topline results from address study of efgartigimod sc in pemphigus

Address study did not meet primary or secondary endpoints pemphigus deprioritized as efgartigimod indication update on ballad study go/no go decision conference call scheduled for today, december 20, 2023, at 8:30am et (2:30pm cet) regulated information – inside information december 20, 2023, 7:00am cet amsterdam, the netherlands — argenx se (euronext & nasdaq: argx), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced topline results from the address study evaluating efgartigimod subcutaneous (sc) (efgartigimod alfa and hyaluronidase-qvfc) in adults with pemphigus vulgaris (pv) and pemphigus foliaceus (pf). the address results show the proportion of pv patients achieving the primary endpoint of complete remission on a minimal dose of steroids (crmin) was not significantly different between efgartigimod sc and placebo.
ARGX Ratings Summary
ARGX Quant Ranking